FDA granted accelerated approval to Ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. November 13, 2013. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm
| This email was sent to aqeel.naseem87.Aqeel7879598@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
